178 related articles for article (PubMed ID: 12529099)
21. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of thrombotic thrombocytopenic purpura].
Ueda Y
Rinsho Ketsueki; 2014 Oct; 55(10):2076-86. PubMed ID: 25297774
[No Abstract] [Full Text] [Related]
23. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.
Tsai HM; Shulman K
Eur J Haematol; 2003 Mar; 70(3):183-5. PubMed ID: 12605663
[TBL] [Abstract][Full Text] [Related]
24. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus.
Kamiya K; Kurasawa K; Arai S; Maezawa R; Hanaoka R; Kumano K; Fukuda T
Mod Rheumatol; 2010 Feb; 20(1):81-5. PubMed ID: 19784542
[TBL] [Abstract][Full Text] [Related]
25. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus.
Limal N; Cacoub P; Sène D; Guichard I; Piette JC
Lupus; 2008 Jan; 17(1):69-71. PubMed ID: 18089688
[No Abstract] [Full Text] [Related]
26. Thrombotic thrombocytopenic purpura: a simpler diagnosis at last?
Mannucci PM
Thromb Haemost; 1999 Nov; 82(5):1380-1. PubMed ID: 10595621
[No Abstract] [Full Text] [Related]
27. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
[TBL] [Abstract][Full Text] [Related]
28. [Thrombotic thrombocytopenic purpura and von Willebrand factor- specific-cleaving enzyme].
Matsumoto M; Fujimura Y
Nihon Naika Gakkai Zasshi; 2000 Jun; 89(6):1137-42. PubMed ID: 10892190
[No Abstract] [Full Text] [Related]
29. Thrombotic thrombocytopenic purpura.
Lämmle B; Kremer Hovinga J; Studt JD; Mansouri Taleghani B; Alberio L
Hematol J; 2004; 5 Suppl 3():S6-11. PubMed ID: 15190269
[No Abstract] [Full Text] [Related]
30. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
31. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
[TBL] [Abstract][Full Text] [Related]
32. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.
Rüfer A; Brodmann D; Gregor M; Kremer Hovinga JA; Lämmle B; Wuillemin WA
Swiss Med Wkly; 2007 Sep; 137(37-38):518-24. PubMed ID: 17990141
[TBL] [Abstract][Full Text] [Related]
34. ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome.
George JN
Curr Hematol Rep; 2005 May; 4(3):167-9. PubMed ID: 15865866
[No Abstract] [Full Text] [Related]
35. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.
van Balen T; Schreuder MF; de Jong H; van de Kar NC
Eur J Haematol; 2014 Jan; 92(1):80-2. PubMed ID: 24118335
[TBL] [Abstract][Full Text] [Related]
36. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
Ferrari S; Palavra K; Gruber B; Kremer Hovinga JA; Knöbl P; Caron C; Cromwell C; Aledort L; Plaimauer B; Turecek PL; Rottensteiner H; Scheiflinger F
Haematologica; 2014 Apr; 99(4):779-87. PubMed ID: 24241492
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application.
Scully M
Blood Rev; 2010 Jan; 24(1):11-6. PubMed ID: 19963308
[TBL] [Abstract][Full Text] [Related]
38. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
39. Current insight into thrombotic thrombocytopenic purpura.
Verbeke L; Delforge M; Dierickx D
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
[TBL] [Abstract][Full Text] [Related]
40. [Multi-facetted clinical presentation of thrombotic thrombocytopenic purpura].
Niemann CU; Jurlander J; Daugaard G; Friis-Hansen L
Ugeskr Laeger; 2009 Jan; 171(5):340-2. PubMed ID: 19176177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
